RareSearch logo

The Wistar Institute Proteomics Facility

50+ personnel
Headquartered in Chandler
Established in 2024
Website

About

Description

The Wistar Institute Proteomics Facility provides mass spectrometry (MS) and sequence analysis of proteins and peptides at maximum sensitivity using state-of-the-art instruments and methods.

Services

  • Life Cycle Assessment (LCA)

    Analyze the lifecycles of products and services with regard to their environmental impacts.

  • Viral Vector Production

    Produce viral vectors for gene therapy and vaccine development.

  • Data Visualization

    Visualize data collected from clinical trials and/or clinical research.

  • Emerging Market Opportunities

    Analyze risks and opportunities in new markets for patient access to new treatments.

  • Adverse Event Reporting

    Monitor and report adverse events related to drug products in clinical trials.

See more

Organization members

  • Amanda Lee

    Communications Director

  • William Kim

    Data Analyst

  • Laura Martinez

    Clinical Trials Coordinator

  • Michael Brown

    Executive Director

  • Robert Garcia

    Fundraising Director

  • Emily Davis

    Research Scientist

Case Studies

https://loremflickr.com/640/480/nature?lock=4331849518153728

Gene Therapy for Alkaptonuria

This project aims to develop gene therapy treatments for Alkaptonuria through collaboration between researchers and patient advocacy groups.
https://loremflickr.com/640/480/nature?lock=1260564410007552

Orphan Drug Designation for Niemann-Pick Disease

This project seeks to obtain orphan drug designation for a new treatment for Niemann-Pick Disease, a rare and fatal genetic disorder.
https://loremflickr.com/640/480/nature?lock=3531880609611776

Biomarker Development for Gaucher Disease

This project aims to develop novel biomarkers for Gaucher Disease to improve diagnosis and monitoring.
https://loremflickr.com/640/480/nature?lock=3612045014466560

Clinical Trial Design for Fibrodysplasia Ossificans Progressiva (FOP)

This project focuses on designing clinical trials for Fibrodysplasia Ossificans Progressiva, a rare and debilitating condition that causes soft tissues to turn into bone.
https://loremflickr.com/640/480/nature?lock=3091072758579200

Health Technology Assessment for Mucopolysaccharidosis (MPS)

This project involves conducting a Health Technology Assessment (HTA) for new treatments targeting Mucopolysaccharidosis, a group of rare metabolic disorders.
See more